The Spectrum of NOTCH3 Variants in an Australian CADASIL Cohort
Genes · 2025
DOI: 10.3390/genes16111353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Solomon K Guyler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Bris…. Hauptthemen laut MEDLINE: Receptor, Notch3, CADASIL. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian National Health and Medical Research Council, Australian Government EIF Super Science Funds.
Abstract (Originalsprache)
Background
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant neurological disorder caused by mutations in the NOTCH3 gene. Disease-causing variants in NOTCH3 are primarily missense variants altering the number of cysteine residues in the translated NOTCH3 protein. The genetic screening of the NOTCH3 gene is currently considered the gold standard for CADASIL diagnosis.
Methods
The Genomics Research Centre has been performing diagnostic genetic testing for CADASIL since 1997. A total of 1281 patient samples suspected of having CADASIL were screened for NOTCH3 mutations from January 1, 1997, to October 1, 2025. Genomic sequencing was performed using Sanger sequencing of selected NOTCH3 exons or using next-generation sequencing to screen the entire NOTCH3 gene.
Results
In total, 12.1% of patients had a cysteine-altering NOTCH3 variant, including 49 variants in exons 2-24, and two variants in non-EGFr encoding exons. We also report the first CADASIL patient who is a compound heterozygote for two known pathogenic cysteine-altering NOTCH3 variants, who presented with a severe early onset of stroke, migraine, and white matter changes.
Conclusions
The compound heterozygosity identified in this patient appears to be associated with an early onset of CADASIL symptoms. Our study contributes to the elucidation of the spectrum of NOTCH3 variants associated with CADASIL. The majority of patients tested for CADASIL in this study did not contain a variant in NOTCH3, indicating that there are other genes or genetic variants contributing to disease in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia.
- Central Analytical Research Facility (CARF), Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia.
- Department of Neurology, Westmead Hospital, Westmead, NSW 2145, Australia.
ORCID-Profile: Neven Maksemous, Heidi G Sutherland, Evelyn Harvey, Lyn R Griffiths
Förderung
- National Health and Medical Research Council
- Australian National Health and Medical Research Council
- Australian Government EIF Super Science Funds
- Queensland University of Technology Postgraduate Research Award
Zitieren
APA
Guyler, S. K., Tsai, J., Maksemous, N., Smith, R. A., Sutherland, H. G., Harvey, E., Duggins, A., & Griffiths, L. R. (2025). The Spectrum of NOTCH3 Variants in an Australian CADASIL Cohort. Genes. https://doi.org/10.3390/genes16111353
Vancouver
Guyler SK, Tsai J, Maksemous N, Smith RA, Sutherland HG, Harvey E, et al. The Spectrum of NOTCH3 Variants in an Australian CADASIL Cohort. Genes. 2025. doi:10.3390/genes16111353
BibTeX
@article{Guyler2025,
author = {Guyler, Solomon K and Tsai, Jasmine and Maksemous, Neven and Smith, Robert A and Sutherland, Heidi G and Harvey, Evelyn and Duggins, Andrew and Griffiths, Lyn R},
title = {The Spectrum of NOTCH3 Variants in an Australian CADASIL Cohort},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16111353}
}
EUVIMED